PE20110388A1 - Formas cristalinas de un derivado de peptido como inhibidores de hcv - Google Patents
Formas cristalinas de un derivado de peptido como inhibidores de hcvInfo
- Publication number
- PE20110388A1 PE20110388A1 PE2011000636A PE2011000636A PE20110388A1 PE 20110388 A1 PE20110388 A1 PE 20110388A1 PE 2011000636 A PE2011000636 A PE 2011000636A PE 2011000636 A PE2011000636 A PE 2011000636A PE 20110388 A1 PE20110388 A1 PE 20110388A1
- Authority
- PE
- Peru
- Prior art keywords
- crystalline forms
- peptide derivative
- hcv inhibitors
- hepatitis
- virus
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 241000711549 Hepacivirus C Species 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910016523 CuKa Inorganic materials 0.000 abstract 1
- 101800001098 Serine protease NS3 Proteins 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- NOJNFULGOQGBKB-UHFFFAOYSA-M sodium;3-[3-tert-butylsulfanyl-1-[[4-(6-ethoxypyridin-3-yl)phenyl]methyl]-5-[(5-methylpyridin-2-yl)methoxy]indol-2-yl]-2,2-dimethylpropanoate Chemical compound [Na+].C1=NC(OCC)=CC=C1C(C=C1)=CC=C1CN1C2=CC=C(OCC=3N=CC(C)=CC=3)C=C2C(SC(C)(C)C)=C1CC(C)(C)C([O-])=O NOJNFULGOQGBKB-UHFFFAOYSA-M 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIERE A UNA FORMA CRISTALINA DE UN DERIVADO DE 2-TIAZOLIL-4-QUINOLINIL-OXI DE FORMULA (1) QUE TIENE UN MODELO DE DIFRACCION DE RAYOS X EN POLVO QUE COMPRENDE PICOS A 4,8; 6,8; 9,6; 13,6; 17,3; 19,8 Y 24,5 GRADOS 2O CUANDO SE MIDE USANDO RADIACION CuKa. SE REFIERE TAMBIEN A UNA FORMA CRISTALINA DE LA SAL DE SODIO DEL COMPUESTO DE FORMULA (1) QUE TIENE UN MODELO DE DIFRACCION DE RAYOS X EN POLVO QUE COMPRENDE PICOS A 5,4; 6,5; 8,7; 10,1; 11,9; 13,0; 18,2; 20,2 Y 24,7 GRADOS 2O Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA SERINA PROTEASA NS3 DEL VIRUS DE LA HEPATITIS C SIENDO UTILES EN EL TRATAMIENTO DE INFECCIONES CAUSADAS POR EL VIRUS DE LA HEPATITIS C
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9729108P | 2008-09-16 | 2008-09-16 | |
| US15082609P | 2009-03-09 | 2009-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20110388A1 true PE20110388A1 (es) | 2011-07-01 |
Family
ID=41268627
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012002419A PE20130307A1 (es) | 2008-09-16 | 2009-09-14 | Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv |
| PE2011000636A PE20110388A1 (es) | 2008-09-16 | 2009-09-14 | Formas cristalinas de un derivado de peptido como inhibidores de hcv |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012002419A PE20130307A1 (es) | 2008-09-16 | 2009-09-14 | Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US8232293B2 (es) |
| EP (2) | EP2331538B1 (es) |
| JP (2) | JP5520301B2 (es) |
| KR (1) | KR101653550B1 (es) |
| CN (1) | CN102159571B (es) |
| AR (1) | AR073298A1 (es) |
| AU (1) | AU2009293494B2 (es) |
| BR (1) | BRPI0918513A2 (es) |
| CA (1) | CA2737055C (es) |
| CL (1) | CL2011000558A1 (es) |
| CO (1) | CO6351741A2 (es) |
| CY (1) | CY1115253T1 (es) |
| DK (1) | DK2331538T3 (es) |
| EA (1) | EA018603B1 (es) |
| EC (1) | ECSP11010878A (es) |
| ES (1) | ES2474992T3 (es) |
| HR (1) | HRP20140666T1 (es) |
| IL (1) | IL210345A (es) |
| MA (1) | MA32633B1 (es) |
| ME (1) | ME01831B (es) |
| MX (1) | MX2011002828A (es) |
| MY (1) | MY153093A (es) |
| NZ (2) | NZ591013A (es) |
| PE (2) | PE20130307A1 (es) |
| PL (1) | PL2331538T3 (es) |
| PT (1) | PT2331538E (es) |
| RS (1) | RS53292B (es) |
| SG (1) | SG189740A1 (es) |
| SI (1) | SI2331538T1 (es) |
| TW (1) | TWI471323B (es) |
| UY (1) | UY32119A (es) |
| WO (1) | WO2010033444A1 (es) |
| ZA (1) | ZA201100096B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| HRP20140666T1 (hr) * | 2008-09-16 | 2014-10-10 | Boehringer Ingelheim International Gmbh | Kristalni oblici derivata 2-tiazolil-4-kinolinil-oksi, snažnog hcv-inhibitora |
| WO2010033443A1 (en) | 2008-09-17 | 2010-03-25 | Boehringer Ingelheim International Gmbh | Combination of hcv ns3 protease inhibitor with interferon and ribavirin |
| WO2010105181A1 (en) * | 2009-03-13 | 2010-09-16 | University Of Toledo | Minimally invasive collapsible cage |
| WO2010107965A1 (en) * | 2009-03-19 | 2010-09-23 | Boehringer Ingelheim International Gmbh | Process for preparing sulfonyl quinolines |
| WO2010129451A1 (en) * | 2009-05-05 | 2010-11-11 | Boehringer Ingelheim International Gmbh | Process for preparing bromo-substituted quinolines |
| MA33491B1 (fr) | 2009-07-07 | 2012-08-01 | Boehringer Ingelheim Int | Composition pharmaceutique pour un inhibiteur de protease virale de l'hépatite c |
| NZ598465A (en) | 2009-10-30 | 2013-10-25 | Boehringer Ingelheim Int | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
| US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
| BR112013007423A2 (pt) | 2010-09-30 | 2016-07-12 | Boehringer Ingelheim Int | terapia combinada no que diz respeito ao tratamento da infecção por hcv |
| EP2658858A4 (en) | 2010-12-30 | 2014-06-25 | Enanta Pharm Inc | MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE |
| MX2013007677A (es) | 2010-12-30 | 2013-07-30 | Abbvie Inc | Inhibidores macrociclicos de serina proteasa de hepatitis. |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| PT107894A (pt) | 2011-10-21 | 2014-10-31 | Abbvie Inc | Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão. |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| GB2515942A (en) | 2011-10-21 | 2015-01-07 | Abbvie Inc | Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV |
| AU2013208024A1 (en) | 2012-01-12 | 2014-07-10 | Boehringer Ingelheim International Gmbh | Stabilized pharmaceutical formulations of a potent HCV inhibitor |
| WO2013137869A1 (en) | 2012-03-14 | 2013-09-19 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population |
| WO2013147750A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| WO2013147749A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient subgenotype populations |
| JP2015512900A (ja) | 2012-03-28 | 2015-04-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法 |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| WO2014138374A1 (en) | 2013-03-08 | 2014-09-12 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
| ES2735355T3 (es) | 2013-03-15 | 2019-12-18 | Gilead Sciences Inc | Inhibidores macrocíclicos y bicíclicos de virus de hepatitis C |
| CA2903831A1 (en) * | 2013-03-15 | 2014-09-25 | Boehringer Ingelheim International Gmbh | Solid oral dosage formulation of hcv inhibitor in the amorphous state |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| WO2022107182A1 (en) * | 2020-11-18 | 2022-05-27 | University Of Petra | A composition of fentanyl and fatty acids, and a method of preparation thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2308955T5 (es) | 1993-09-28 | 2012-04-03 | R.P. Scherer Gmbh | Fabricación de cápsulas de gelatina blanda |
| AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
| SK9742002A3 (en) * | 2000-01-07 | 2003-02-04 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| UY28240A1 (es) * | 2003-03-27 | 2004-11-08 | Boehringer Ingelheim Pharma | Fases cristalinas de un potente inhibidor de la hcv |
| DE602004010137T2 (de) * | 2003-05-21 | 2008-09-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verbindungen als hepatitis c inhibitoren |
| JP5156374B2 (ja) * | 2004-05-25 | 2013-03-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 非環式ｈｃｖプロテアーゼインヒビターの調製方法 |
| HRP20140666T1 (hr) * | 2008-09-16 | 2014-10-10 | Boehringer Ingelheim International Gmbh | Kristalni oblici derivata 2-tiazolil-4-kinolinil-oksi, snažnog hcv-inhibitora |
| US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
-
2009
- 2009-09-14 HR HRP20140666AT patent/HRP20140666T1/hr unknown
- 2009-09-14 PE PE2012002419A patent/PE20130307A1/es active IP Right Grant
- 2009-09-14 PT PT97924930T patent/PT2331538E/pt unknown
- 2009-09-14 DK DK09792493.0T patent/DK2331538T3/da active
- 2009-09-14 SI SI200930919T patent/SI2331538T1/sl unknown
- 2009-09-14 PL PL09792493T patent/PL2331538T3/pl unknown
- 2009-09-14 ES ES09792493.0T patent/ES2474992T3/es active Active
- 2009-09-14 PE PE2011000636A patent/PE20110388A1/es not_active Application Discontinuation
- 2009-09-14 EP EP09792493.0A patent/EP2331538B1/en active Active
- 2009-09-14 NZ NZ591013A patent/NZ591013A/xx not_active IP Right Cessation
- 2009-09-14 JP JP2011527015A patent/JP5520301B2/ja active Active
- 2009-09-14 ME MEP-2014-43A patent/ME01831B/me unknown
- 2009-09-14 WO PCT/US2009/056772 patent/WO2010033444A1/en not_active Ceased
- 2009-09-14 SG SG2013024864A patent/SG189740A1/en unknown
- 2009-09-14 RS RS20140230A patent/RS53292B/sr unknown
- 2009-09-14 CN CN200980136131.XA patent/CN102159571B/zh not_active Expired - Fee Related
- 2009-09-14 EA EA201100482A patent/EA018603B1/ru not_active IP Right Cessation
- 2009-09-14 KR KR1020117004209A patent/KR101653550B1/ko not_active Expired - Fee Related
- 2009-09-14 EP EP13188665.7A patent/EP2687526A1/en not_active Withdrawn
- 2009-09-14 MX MX2011002828A patent/MX2011002828A/es active IP Right Grant
- 2009-09-14 MY MYPI20111140 patent/MY153093A/en unknown
- 2009-09-14 AU AU2009293494A patent/AU2009293494B2/en not_active Ceased
- 2009-09-14 BR BRPI0918513A patent/BRPI0918513A2/pt not_active Application Discontinuation
- 2009-09-14 CA CA2737055A patent/CA2737055C/en not_active Expired - Fee Related
- 2009-09-14 NZ NZ602163A patent/NZ602163A/xx not_active IP Right Cessation
- 2009-09-15 AR ARP090103540A patent/AR073298A1/es not_active Application Discontinuation
- 2009-09-15 US US12/559,927 patent/US8232293B2/en active Active
- 2009-09-15 UY UY0001032119A patent/UY32119A/es not_active Application Discontinuation
- 2009-09-15 TW TW98131069A patent/TWI471323B/zh not_active IP Right Cessation
-
2010
- 2010-12-29 IL IL210345A patent/IL210345A/en active IP Right Grant
-
2011
- 2011-01-04 ZA ZA2011/00096A patent/ZA201100096B/en unknown
- 2011-03-09 EC EC2011010878A patent/ECSP11010878A/es unknown
- 2011-03-14 MA MA33699A patent/MA32633B1/fr unknown
- 2011-03-16 CO CO11032830A patent/CO6351741A2/es not_active Application Discontinuation
- 2011-03-16 CL CL2011000558A patent/CL2011000558A1/es unknown
-
2012
- 2012-07-03 US US13/541,158 patent/US8362035B2/en active Active
-
2013
- 2013-12-09 JP JP2013253812A patent/JP2014062116A/ja not_active Withdrawn
-
2014
- 2014-07-11 CY CY20141100526T patent/CY1115253T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20110388A1 (es) | Formas cristalinas de un derivado de peptido como inhibidores de hcv | |
| EA200970805A1 (ru) | Ингибиторы серинпротеаз для лечения hcv инфекций | |
| EA201100795A1 (ru) | Фармацевтическая композиция эффективного ингибитора всг для перорального введения | |
| EA026667B9 (ru) | Фармацевтическая композиция для лечения вируса гепатита с | |
| RU2013109393A (ru) | Безилатная соль ингибитора втк | |
| MX2009011019A (es) | Difenil-dihidro-imidazopiridinonas. | |
| CY1117113T1 (el) | Αναστολεις πρωτεασης σερινης hcv λαμβανομενοι απο μακροκυκλικη προλινη | |
| WO2013074386A3 (en) | Hcv ns3 protease inhibitors | |
| CL2008003431A1 (es) | Compuestos derivados de nucleosidos 2',4' sustituidos; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su metodo de preparacion; y su uso para el tratamiento y/o la prevencion de cualquier condicion resultante de una infeccion por vhb, vhc o vih. | |
| CY1110835T1 (el) | Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c | |
| NZ609146A (en) | Modified 4’-nucleosides as antiviral agents | |
| EA200800670A1 (ru) | Ингибиторы сериновых протеаз | |
| UA102677C2 (uk) | Хіноксалінвмісні сполуки як інгібітори вірусу гепатиту с | |
| ME02558B (me) | Inhibitori replikacije virusa gripa | |
| MY164469A (en) | Hcv ns3 protease inhibitors | |
| MX2009012613A (es) | Tiazoles substituidos por heteroarilo y su uso como agentes antivirales. | |
| BR112013002729A2 (pt) | inibidores de vírus de hepatite c | |
| CL2013003171A1 (es) | Compuesto macrociclico derivado de prolina inhibidor de la proteasa serina ns3; su composicion farmaceutica; y su uso en el tratamiento de una infeccion viral, en particular una infeccion causada por el virus de la hepatitis c (vhc). | |
| MX2011006631A (es) | Inhibidores de proteasa ns3 del virus hcv. | |
| EA201270275A1 (ru) | Кристаллическое соединение пиридазина | |
| AR073769A1 (es) | Inhibidores de la integrasa del vih derivados de azepina y oxazepinas condensadas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de infecciones por vih. | |
| BR112013028679A2 (pt) | inibidores do vírus da hepatite c | |
| MX2010008108A (es) | Inhibidores de proteasa de serina de tripéptido de virus de hepatitis c (hcv) que contienen heteroarilo. | |
| AR083256A1 (es) | Formas en estado solido del acido (e)-3-[2-(1-{[2-(5-bromo-pirimidin-2-il)-3-ciclopentil-1-metil-1h-indol-6-carbonil]-amino}-ciclobutil)-3-metil-3h-bencimidazol-5-il]-acrilico | |
| PH12015502258A1 (en) | Solid oral dosage formulation of hcv inhibitor in the amorphous state |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |